Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in relapsed or refractory classical Hodgkin lymphoma
NCT02684292Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jan 2026
01
Overview
A Phase 3 trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co.. Started May 2016; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02684292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684292.